December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

125.92 -0.26 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
51 52 Next >
News headline image
Price Over Earnings Overview: Abbott Laboratories ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results ↗
 
Via Benzinga
News headline image
Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend. 
Via MarketBeat
News headline image
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast ↗
Abbott Laboratories reported third-quarter 2024 sales of $10.64B, with Medical Devices leading 11.7% sales growth. Adjusted EPS of $1.21 beat analyst expectations. Full-year guidance was updated. 
Via Benzinga
News headline image
Abbott Labs Earnings Edge Past Q3 Views, Led By Medical Devices ↗
Medical devices led organic sales growth. 
Via Investor's Business Daily
News headline image
A Glimpse of Abbott Laboratories's Earnings Potential ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock ↗
 
Via Benzinga
News headline image
A Look Into Abbott Laboratories Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Abbott Laboratories? ↗
 
Via Benzinga
News headline image
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips ↗
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
News headline image
Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗
 
Via Benzinga
News headline image
Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone ↗
 
Via Benzinga
News headline image
Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday ↗
 
Via Benzinga
News headline image
Navigating 6 Analyst Ratings For Abbott Laboratories ↗
 
Via Benzinga
News headline image
Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗
Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
Via Talk Markets
News headline image
Columbus Day: Is Stock Market Open Today? ↗
Investors should brace for a busy week with earnings reports from major companies. 
Via Benzinga
News headline image
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth ↗
Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion. 
Via Benzinga
News headline image
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
3 Magnificent Dividend Stocks to Buy in October ↗
These dividend stocks are great picks as the fall season gets underway. 
Via The Motley Fool
News headline image
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades ↗
Investors can find market-trouncing blue chip stocks in the healthcare industry. 
Via The Motley Fool
News headline image
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
News headline image
Down More Than 50%, Is DexCom Stock a Bargain Now? ↗
Demand for blood glucose monitors is strong, but DexCom isn't the only competitor in this lucrative market. 
Via The Motley Fool
News headline image
2 Excellent Dividend Stocks to Buy With Less Than $200 ↗
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
Via The Motley Fool
News headline image
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
News headline image
Abbott Laboratories' Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst ↗
Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech growth and attractive valuation. 
Via Benzinga
News headline image
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
20 S&P 500 Stocks That Move The Most When The Fed Starts Cutting Interest Rates ↗
Investors are anticipating the first cut to the federal funds rate in over four years at the September FOMC meeting. The market is divided on the magnitude of the cut, which could trigger significant... 
Via Benzinga
Topics Economy Stocks
News headline image
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
News headline image
Can AbbVie Regain Its Status As a Top Dividend Growth Stock? ↗
The dividend growth powerhouse is turning the corner. 
Via The Motley Fool
News headline image
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy? ↗
The company continues to flex its innovative muscles. 
Via The Motley Fool
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.